AAKAAR AAKAAR Q4 FY26 results (Jan–Mar 2026) and concall
Aakaar Medical Technologies reported a strong H2 FY26, recovering from a challenging H1, with significant revenue and profit growth, improved margins, and reduced debtor days. The company launched several new high-potential products and expanded its customer base, while strategically deploying IPO capital for working capital rationalization. Management expressed confidence in sustaining growth and margins through operational efficiency and an evolving distribution model.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q4 FY25 | Q2 FY26 | Q4 FY26 |
|---|---|---|---|
| Revenue | 34 | 25 | 42 |
| EBITDA | 8 | 0 | 10 |
| Net profit | 6 | -1 | 7 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
